Jon D. Piganelli
Biochemistry, Genetics and Molecular Biology · Indiana University
Publications
122
Citations
6,248
Est. group size
—
Recurring co-author estimate
Active years
33
Publishing since 1994
Jon D. Piganelli studies type 1 diabetes, an autoimmune disease in which the body's own immune cells attack the insulin-producing beta cells of the pancreas. His work explores how immune cells (especially T cells) become activated against these beta cells, how metabolism and cellular stress influence this process, and how existing drugs or new approaches might prevent or reverse the disease. He also investigates broader questions in immune function, pancreatic cell development, and inflammation-related conditions.
After a peak around 2018, output dipped and has grown again since 2024, averaging roughly four publications per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Soluble LAG-3 Identifies a Dynamic Early T Cell Activation Window in self-reactivity, Type 1 Diabetes, and Broader Immune Responses
bioRxiv (Cold Spring Harbor Laboratory) · 2026
- Islet-intrinsic sex differences in inflammatory signaling contribute to autoimmune diabetes susceptibility
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Decoding the immune dance: Unraveling the interplay between beta cells and type 1 diabetes
Molecular Metabolism · 2024
- Acinar to β-like cell conversion through inhibition of focal adhesion kinase
Nature Communications · 2024
- The Chicken or the Egg Dilemma: Understanding the Interplay between the Immune System and the β Cell in Type 1 Diabetes
Cold Spring Harbor Perspectives in Medicine · 2024
- Repurposing Cancer Drugs for Type 1 Diabetes Prevention
ASEAN Journal of Psychiatry · 2024
- 226-LB: Repurposing a Cancer Drug, AZD6738 (ATRi), for the Prevention of Type 1 Diabetes
Diabetes · 2023
- Epithelial NAD+ depletion drives mitochondrial dysfunction and contributes to intestinal inflammation
Frontiers in Immunology · 2023
- An orally available cancer drug AZD6738 prevents type 1 diabetes
Frontiers in Immunology · 2023
- Myeloid FoxO1 depletion attenuates hepatic inflammation and prevents nonalcoholic steatohepatitis
Journal of Clinical Investigation · 2022
- Focal adhesion kinase-mediated signaling controls the onset of pancreatic cell differentiation
Development · 2022
- Editorial: Immunopathology of Type 1 Diabetes
Frontiers in Immunology · 2022
- Glycolysis Inhibition Induces Functional and Metabolic Exhaustion of CD4+ T Cells in Type 1 Diabetes
Frontiers in Immunology · 2021
- The Role of β Cell Stress and Neo-Epitopes in the Immunopathology of Type 1 Diabetes
Frontiers in Endocrinology · 2021
- Auto-antigen and Immunomodulatory Agent–Based Approaches for Antigen-Specific Tolerance in NOD Mice
Current Diabetes Reports · 2021
- Frontiers in Immunology×6
- Diabetes×5
- bioRxiv (Cold Spring Harbor Laboratory)×5
- The Journal of Immunology×4
- Cell Reports×2
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile